Up next


FDA board votes to approve gene therapy for Duchenne muscular dystrophy

73 Views
CNBC Television
0
Published on 15 May 2023 / In News & Politics

David Nierengarten, Wedbush Securities managing director, joins 'Closing Bell Overtime' to discuss Sarepta shares after the FDA panel votes to approve gene therapy for Duchenne muscular dystrophy.

Show more
0 Comments sort Sort By

Up next